Compound development

We learn from nature. Our peptides undergo a stabilization optimization to generate cell permeable and stable compounds.

STX100 series

STX100 is a stabilized peptide that inhibits an interaction essential in the Homologous Recombination (HR) DNA repair pathway. We are developing this compound as a monotherapy for specific types of cancers which are dependent on HR for chemotherapy evasion. 

Our drug development pipeline

  • Twitter
  • LinkedIn Social Icon

© 2020 by SyntheX